Leukaemia Diagnostic Interpretation (Part 2) (Accredited)

This programme is run in conjunction with the Leukaemia Immunophenotyping (Part 1) programme.


This programme is designed to provide for a more realistic sample immunophenotyping process.


Please note that a laboratory who registers for Part One is automatically registered for Part Two and is required to complete both parts. However Part Two only registration is allowed for laboratories that do not routinely undertake immunophenotyping.


Individual registration for Part Two is also encouraged for continued professional development.


This part of the trial is designed to assess a laboratory’s ability to diagnose leukaemia using a full spectrum of laboratory tests. No samples are issued for this, the programme is totally web based. This part of the programme issues and examines a wide variety of cases. Each trial will consist of:


  • A full consensus phenotype (derived from the corresponding Part One exercise)
  • A detailed case history
  • Several digital blood/marrow smears for morphological analysis using, where possible, a variety of stains
  • Cytogenetics and Molecular Genetics data


Participants are expected to use this information and in the diagnosis section provide a suitable diagnosis based on the World Health Organization (WHO) classification system.


This programme issues samples a minimum of 4 times per annum and a maximum of 6.


Trials for this programme are live/open for a minimum of 3 weeks.

Please Note: Trials issued/closing in August or December are extended by 1 week.

An automated email is sent 2 days prior to the trial closing, to any participant that has not returned results, warning them of the trial closure date. 


No activities in relation to this EQA programme are subcontracted.


PLEASE NOTE - A new diagnosis option has been added to the Leukaemia Diagnostic Interpretation programme.


In certain cases UK NEQAS LI appreciates that identification of the Lineage and Differentiation in a case is possible but a final diagnosis is not based on the clinical information provided.

As a result, we have included an option of 'Final diagnosis cannot be made based on the clinical information' in the diagnosis section of the result entry table. 


***New for 2024-2025***


The uptake of the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasm and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data are currently being assessed in the Leukaemia Diagnostic Interpretation programme. Pending the findings, changes will be made to the programme to reflect current practice. 


To register for this programme, please click here.

Participant Instructions for Viewing Precipoint Scanned Images
Participant Instructions for Viewing Pre[...]
Adobe Acrobat document [829.7 KB]
Example Leukaemia Diagnostic Interpretation Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
Example LDI Part 2 Report.pdf
Adobe Acrobat document [2.0 MB]
Leukaemia Diagnostic Interpretation Performance Monitoring System
Performance Monitoring System for Leukae[...]
Adobe Acrobat document [27.8 KB]
Changes to Diagnosis Classification for Leukaemia Diagnostic Interpretation
Changes to Diagnosis Classification in t[...]
Adobe Acrobat document [730.1 KB]
Leukaemia Diagnostic Table
Leukaemia Diagnostic Table.pdf
Adobe Acrobat document [150.1 KB]
Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 14/06/2024 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).